Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Completed

Conditions studied: Neuroendocrine Tumors

In brief

The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.

Key facts

Study ID

NCT03112694

Run by

Ipsen

People needed

93

Starts

2017-04-04

Expected to finish

2017-11-02

Last updated by the study team

2020-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females age 18 years or older at time of locally advanced or metastatic diagnosis
• Patients with a confirmed diagnosis of locally advanced or metastatic Gastroenteropancreatic neuroendocrine tumour (GEP-NET)
• Patients who switched treatment from long acting octreotide LAR to lanreotide, where both treatments were received for the treatment of locally advanced or metastatic GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii. Treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy (rescue SSA# use permitted)

You may not qualify if…

• Patients with other malignant disease
• Patients who participated in a concomitant clinical trial related to treatment of GEP-NET
• Patients being treated with a Somatostatin analogue (SSA) in combination with other NET treatments excluding rescue SSA#
• Patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for GEP-NET during the interval between octreotide and lanreotide
• Patients with NET familial genetic syndrome (i.e., MEN1)

Where it is running

• Moffitt Cancer Center — Tampa, Florida, United States
• Cancer Center of Kansas — Wichita, Kansas, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• Mercy Medical Center — Baltimore, Maryland, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Mayo Clinic — Rochester, Minnesota, United States
• National Transitional Research — East Setauket, New York, United States
• Allegheny Cancer Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.